Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIII) Net Income towards Common Stockholders (2020 - 2025)

P3 Health Partners (PIII) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$69.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income towards Common Stockholders rose 32.46% year-over-year to -$69.5 million, compared with a TTM value of -$351.9 million through Sep 2025, down 58.49%, and an annual FY2024 reading of -$310.4 million, down 66.49% over the prior year.
  • Net Income towards Common Stockholders was -$69.5 million for Q3 2025 at P3 Health Partners, down from -$43.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$10.6 million in Q1 2022 and bottomed at -$903.1 million in Q2 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$128.4 million, with a median of -$46.9 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 2965.07% in 2022, then surged 96.97% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$60.2 million in 2021, then plummeted by 783.82% to -$532.3 million in 2022, then soared by 93.0% to -$37.3 million in 2023, then tumbled by 421.74% to -$194.6 million in 2024, then soared by 64.3% to -$69.5 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for PIII at -$69.5 million in Q3 2025, -$43.7 million in Q2 2025, and -$44.2 million in Q1 2025.